TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit

Rhea-AI Summary

TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company, announced participation in a fireside chat at the Jefferies Cell Therapy Virtual Summit on October 5, 2020, at 2:00 PM E.T. This session will be held virtually, and a live webcast will be available on the company's Investors page. TCR² focuses on developing novel T cell therapies targeting solid tumors and hematological malignancies, with their lead candidates, TC-210 and TC-110, currently in Phase 1/2 clinical trials.

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the Jefferies Cell Therapy Virtual Summit on Monday, October 5, 2020 at 2:00pm E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at https://investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors or hematological malignancies. TCR²’s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while secreting lower levels of cytokine release. The Company’s lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. The Company’s lead TRuC-T cell product candidate targeting hematological malignancies, TC-110, is currently being studied in a Phase 1/2 clinical trial to treat patients with CD19-positive adult acute lymphoblastic leukemia (aALL) and with aggressive or indolent non-Hodgkin lymphoma (NHL). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contact:

Carl Mauch
Director, Investor Relations and Corporate Communications
TCR² Therapeutics Inc.
(617) 949-5667
carl.mauch@tcr2.com

FAQ

When will TCR² Therapeutics participate in the Jefferies Cell Therapy Virtual Summit?

TCR² Therapeutics will participate in the Jefferies Cell Therapy Virtual Summit on October 5, 2020, at 2:00 PM E.T.

Where can I watch the TCR² Therapeutics presentation from the summit?

A live webcast of the presentation will be available on the Investors page of TCR² Therapeutics' website.

What are TCR² Therapeutics' lead product candidates?

TCR² Therapeutics' lead product candidates are TC-210, targeting solid tumors, and TC-110, targeting hematological malignancies.

What diseases are targeted by TCR² Therapeutics' TRuC-T cell therapies?

TCR² Therapeutics' TRuC-T cell therapies target solid tumors such as non-small cell lung cancer and ovarian cancer, as well as hematological malignancies like acute lymphoblastic leukemia.

How does TCR² Therapeutics' TRuC-T cell technology compare to CAR-T cells?

In preclinical studies, TRuC-T cells have shown superior anti-tumor activity compared to CAR-T cells while producing lower levels of cytokine release.